Skip to Main Content (Press Enter)

Logo UNIMORE
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze

UNI-FIND
Logo UNIMORE

|

UNI-FIND

unimore.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze
  1. Pubblicazioni

Side Effects of Immunosuppressant Drugs After Liver Transplant

Articolo
Data di Pubblicazione:
2025
Citazione:
Side Effects of Immunosuppressant Drugs After Liver Transplant / Gabrielli, F.; Bernasconi, E.; Toscano, A.; Avossa, A.; Cavicchioli, A.; Andreone, P.; Gitto, S.. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 18:3(2025), pp. 1-30. [10.3390/ph18030342]
Abstract:
Liver transplantation (LT) is the standard of care for both end-stage liver failure and hepatocellular carcinoma (HCC). Side effects of the main used immunosuppressive drugs have a noteworthy impact on the long-term outcome of LT recipients. Consequently, to achieve a balance between optimal immunosuppression and minimal side effects is a cornerstone of the post-LT period. Today, there are no validated markers for overimmunosuppression and underimmunosuppression, only a few drugs have therapeutic drug monitoring, and immunosuppression regimens vary from center to center and from country to country. Currently, there are many drugs with different efficacy and safety profiles. Using different agents permits a decrease in the dosage and minimizes the toxicities. A small subset of recipients achieves immunotolerance with the chance to stop immunosuppressive therapy. This article focuses on the side effects of immunosuppressive drugs, which significantly impact long-term outcomes for LT recipients. The primary aim is to highlight the balance between achieving effective immunosuppression and minimizing adverse effects, emphasizing the role of personalized therapeutic strategies. Moreover, this review evaluates the mechanisms of action and specific complications associated with immunosuppressive agents. Finally, special attention is given to strategies for reducing immunosuppressive burdens, improving patient quality of life, and identifying immunotolerant individuals.
Tipologia CRIS:
Articolo su rivista
Keywords:
MASLD; cardiovascular disease; frailty; immunosuppression; metabolic syndrome; nephrotoxicity; orthotopic liver transplant; osteoporosis; side effect; tacrolimus
Elenco autori:
Gabrielli, F.; Bernasconi, E.; Toscano, A.; Avossa, A.; Cavicchioli, A.; Andreone, P.; Gitto, S.
Autori di Ateneo:
ANDREONE Pietro
Gabrielli Filippo
Link alla scheda completa:
https://iris.unimore.it/handle/11380/1377889
Link al Full Text:
https://iris.unimore.it//retrieve/handle/11380/1377889/895083/pharmaceuticals-18-00342-v2.pdf
Pubblicato in:
PHARMACEUTICALS
Journal
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 25.10.3.0